Salmefamol is a beta2-adrenergic receptor agonist, a type of medication that opens up the airways in the lungs. It is used to treat asthma and chronic obstructive pulmonary disease (COPD). Salmefamol is a racemic mixture of two enantiomers, the R-enantiomer being the active form. It acts by stimulating beta2-adrenergic receptors in the smooth muscle of the bronchi, causing relaxation and bronchodilation. Salmefamol is typically administered by inhalation. It is a relatively long-acting bronchodilator, with effects lasting for several hours. Salmefamol is a synthetic compound that was first synthesized in the 1960s. It is a potent bronchodilator with a relatively long duration of action. Salmefamol is effective in treating asthma and COPD. However, it is not as widely used as other beta2-adrenergic receptor agonists, such as albuterol and salbutamol. This is due to the fact that salmefamol is associated with a higher risk of adverse effects, such as tachycardia and tremor. It is generally considered safe for short-term use, but long-term use can lead to tolerance and dependence. Salmefamol is a relatively expensive drug, which may limit its use.'
salmefamol: beta adrenergic stimulant similar to albuterol; used as a bronchodilator with little effect on the cardiovascular system; minor descriptor (77-86); on-line & INDEX MEDICUS search ETHANOLAMINES (77-86); RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 86805 |
| CHEMBL ID | 2107072 |
| SCHEMBL ID | 18458 |
| MeSH ID | M0263180 |
| Synonym |
|---|
| HY-10998 |
| ahr 3929 |
| brn 2162832 |
| 1,3-benzenedimethanol, 4-hydroxy-alpha(sup 1)-(((2-(4-methoxyphenyl)-1-methylethyl)amino)methyl)- |
| salmefamolum [inn-latin] |
| einecs 242-662-5 |
| 1-(4-hydroxy-3-hydroxymethylphenyl)-2-(4-methoxy-alpha-methylphenethylamino)ethanol |
| alpha-((p-methoxy-alpha-methylphenethylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha'-diol |
| ah 3923 |
| ah-3923 |
| 18910-65-1 |
| salmefamol |
| 4-[1-hydroxy-2-[1-(4-methoxyphenyl)propan-2-ylamino]ethyl]-2-(hydroxymethyl)phenol |
| unii-q56sey8x9j |
| salmefamol [inn:ban] |
| salmefamolum |
| q56sey8x9j , |
| CHEMBL2107072 |
| CS-0358 |
| SCHEMBL18458 |
| salmefamol [inn] |
| 4-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methyl-ethyl]amino]ethyl]-2-(hydroxymethyl)phenol |
| ah 3923;ah-3923; ah3923 |
| 1,3-benzenedimethanol, 4-hydroxy-alpha1-[[[2-(4-methoxyphenyl)-1-methylethyl]amino]methyl]- |
| 4-(1-hydroxy-2-{[1-(4-methoxyphenyl)propan-2-yl]amino}ethyl)-2-(hydroxymethyl)phenol |
| DTXSID80864864 |
| AKOS040744822 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " The reaction patterns were similar for isoprenaline and somatostatin, whereas salmefamol induced an inhibition of longer duration and with dissimilar dose-response kinetics." | ( Beta-adrenergic agonists inhibit gastric acid and pepsin secretion through somatostatin release in dogs. Bech, K; Uvnäs-Moberg, K, 1986) | 0.5 |
| " Dose-response experiments with five doses of pentagastrin or histamine (single-dose studies) and two doses of beta 2-agonist suggested a change after vagotomy in the mechanisms of inhibition of gastric acid secretion: for pentagastrin, from a non-competitive type to an uncompetitive type, and for histamine, from a competitive type to a non-significant inhibition." | ( Effect of beta 2-sympathomimetic on pentagastrin- and histamine-stimulated gastric acid secretion in vagotomized gastric fistula dogs. Andersen, D; Gottrup, F; Ornsholt, J, 1980) | 0.26 |
| " Dose-response experiments with five doses of urecholine and two doses of the beta2-agonist showed a decrease in maximal response, and transformation of the curve suggested an unchanged D50." | ( Effect of a beta2-sympathomimetic on urecholine-stimulated gastric acid secretion in dogs. Gottrup, F, 1981) | 0.26 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 9 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (25.48) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||